Rani Therapeutics Inc.

NASDAQ: RANI · Real-Time Price · USD
0.56
0.01 (1.82%)
At close: Aug 18, 2025, 1:09 PM

Rani Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1.2M 1.2M 1.03M 2.75M 2.75M 2.75M 2.75M n/a n/a n/a n/a -2.72M -2.72M -756K n/a 2.93M 3.04M 1.13M
Cost of Revenue
499K 514K 762K 989K 1.21M 1.4M 1.15M 1.34M 1.21M 1.04M 1.31M 1.01M 783K 501K 233K 120K n/a n/a
Gross Profit
701K 686K 266K 1.76M 1.54M 1.35M 1.6M -1.34M -1.21M -1.04M -1.31M -3.73M -3.5M -1.26M -233K 2.81M 3.04M 1.13M
Operating Income
-49.27M -51.29M -53.31M -51.79M -57.85M -63.62M -66.1M -70.15M -68.64M -66.19M -63.45M -40.2M -51.64M -41.05M -32.47M -43.18M -18.23M -16.36M
Interest Income
1.15M 1.43M 1.76M 2.08M 2.5M 2.96M 3.3M 3.44M 2.98M 2.12M 1.25M 445K 79K 57K 89K 73K 73K 72K
Pretax Income
-42.4M -49.07M -56.58M -54.92M -60.53M -65.83M -67.88M -71.21M -69.19M -66.34M -63.28M -59.24M -71.58M -61.26M -53.05M -45.45M -19.66M -16.89M
Net Income
-29.69M -29.8M -30.02M -28.17M -30.58M -33.08M -33.97M -44.22M -51.23M -57.89M -63.34M -59.23M -46.16M -35.68M -27.45M -30.93M -30.67M -27.9M
Selling & General & Admin
21.7M 23.11M 23.7M 23.84M 24.84M 25.64M 26.25M 27.74M 28.35M 27.46M 26.84M 25.69M 34.27M 31.42M 27.83M 23.71M 8.73M 6.16M
Research & Development
25.06M 25.67M 26.68M 27.48M 32.53M 37.5M 39.62M 42.4M 40.29M 38.73M 36.61M 33.64M 36.49M 30.73M 26.48M 22.4M 12.53M 11.33M
Other Expenses
3.71M 3.71M 3.71M 227K 227K 227K 227K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
50.48M 52.49M 54.09M 51.54M 57.6M 63.37M 66.1M 70.15M 68.64M 66.19M 63.45M 59.33M 70.77M 62.14M 54.32M 46.11M 21.26M 17.49M
Interest Expense
2.4M 2.79M 5.03M 5.2M 5.18M 5.17M 5.08M 4.51M 3.54M 2.28M 1.07M 352K 110K 279K 467K 549K 503K 336K
Selling & Marketing Expenses
n/a n/a -248K -475K -475K -475K -227K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
50.48M 52.49M 54.34M 51.79M 57.85M 63.62M 66.1M 70.15M 68.64M 66.19M 63.45M 59.33M 70.77M 62.14M 54.32M 46.11M 21.26M 17.49M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a -41K -148K 6K 69K -12K 132K -21K -41K 93K 61K 66K
Shares Outstanding (Basic)
36.54M 33.44M 32.66M 28.84M 26.32M 26.03M 25.87M 25.55M 25.34M 25.24M 24.91M 24.47M 24.37M 21.41M 19.53M 19.44M 46.9M 18.74M
Shares Outstanding (Diluted)
36.54M 33.44M 32.66M 28.84M 26.32M 26.03M 25.87M 25.55M 25.34M 25.24M 24.91M 24.47M 24.37M 21.41M 19.53M 19.44M 46.9M 18.74M
EPS (Basic)
-0.91 -0.99 -1.06 -1.06 -1.18 -1.29 -1.33 -1.76 -2.06 -2.35 -2.67 -2.65 -2.15 -1.61 -1.26 -1.47 -1.46 -1.48
EPS (Diluted)
-0.91 -0.99 -1.06 -1.06 -1.18 -1.29 -1.33 -1.76 -2.06 -2.35 -2.67 -2.65 -2.15 -1.61 -1.26 -1.47 -1.46 -1.48
EBITDA
-47.98M -49.3M -50.52M -48.73M -54.14M -59.26M -61.46M -65.18M -64.25M -62.99M -61.21M -58.19M -71.01M -60.51M -52.08M -44.4M -18.63M -16M
EBIT
-48.13M -49.86M -51.55M -49.71M -55.34M -60.66M -62.8M -66.7M -65.65M -64.06M -62.2M -58.89M -71.48M -60.98M -52.58M -44.92M -19.18M -16.57M
Depreciation & Amortization
776K 1.03M 1.03M 989K 1.21M 1.4M 1.34M 1.52M 1.4M 1.23M 1.31M 1.01M 783K 629K 497K 526K 550K 572K